First studies with an LMP-2 DC vaccine in patients with NPC showed specific CD8+ T-cell responses directed against LMP-2, which plays a critical role in controlling and preventing the recurrence and metastasis formation of NPC [312]. Here, CD8A is linked to nasopharyngeal carcinoma.